Brief: Medicenna Updates Efficacy Results From Phase 2B Recurrent Gbm Trial At Asco 2020
29/05/2020 13:55
Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA UPDATES EFFICACY RESULTS FROM PHASE 2B RECURRENT
GBM
TRIAL AT ASCO 2020
Source text for Eikon: ID:nCNWkRGw8a
Further company coverage: MDNA.TO
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results